ZA201006157B - Modified release formulations of hmg coa reductase inhibitors - Google Patents

Modified release formulations of hmg coa reductase inhibitors

Info

Publication number
ZA201006157B
ZA201006157B ZA2010/06157A ZA201006157A ZA201006157B ZA 201006157 B ZA201006157 B ZA 201006157B ZA 2010/06157 A ZA2010/06157 A ZA 2010/06157A ZA 201006157 A ZA201006157 A ZA 201006157A ZA 201006157 B ZA201006157 B ZA 201006157B
Authority
ZA
South Africa
Prior art keywords
coa reductase
release formulations
modified release
reductase inhibitors
hmg coa
Prior art date
Application number
ZA2010/06157A
Other languages
English (en)
Inventor
Satish Kumar Dalal
Ashish Ashokrao Deshmukh
Srirupa Das
Shirishkumar Kulkarni
Sheetal Kulkarni
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ZA201006157B publication Critical patent/ZA201006157B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2010/06157A 2008-01-30 2010-08-27 Modified release formulations of hmg coa reductase inhibitors ZA201006157B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN145KO2008 2008-01-30
PCT/IN2009/000069 WO2009095934A1 (en) 2008-01-30 2009-01-30 Modified release formulations of hmg coa reductase inhibitors

Publications (1)

Publication Number Publication Date
ZA201006157B true ZA201006157B (en) 2011-05-25

Family

ID=40638221

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/06157A ZA201006157B (en) 2008-01-30 2010-08-27 Modified release formulations of hmg coa reductase inhibitors

Country Status (8)

Country Link
US (1) US20110003837A1 (https=)
EP (1) EP2285353A1 (https=)
JP (1) JP2011510974A (https=)
AU (1) AU2009208610A1 (https=)
BR (1) BRPI0906728A2 (https=)
MX (1) MX2010008466A (https=)
WO (1) WO2009095934A1 (https=)
ZA (1) ZA201006157B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590161B2 (en) * 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) * 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
IL149422A0 (en) * 1999-11-03 2002-11-10 Smith Howard J & Ass Pty Ltd Oral pharmaceutical compositions for liver therapy
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
US20050147620A1 (en) * 2004-01-05 2005-07-07 Karl Bozicevic Cinnamon formulation for reducing cholesterol and/or glucose levels
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid

Also Published As

Publication number Publication date
JP2011510974A (ja) 2011-04-07
MX2010008466A (es) 2010-10-25
US20110003837A1 (en) 2011-01-06
AU2009208610A1 (en) 2009-08-06
BRPI0906728A2 (pt) 2015-07-07
WO2009095934A1 (en) 2009-08-06
EP2285353A1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
IL211056A0 (en) Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
IL198349A0 (en) Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors
IL211344A0 (en) An extended release pharmaceutical composition of entacapone or salts thereof
EP2318007A4 (en) Novel pyrrolidemers of S-nitrosoglutathione reductase as a therapeutic agent
ZA201000318B (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
SG10201703242XA (en) Compositions and methods for inhibiting expression of transthyretin
ZA201205374B (en) Novel s-nitrosoglutathione reductase inhibitors
EP2315590A4 (en) PYRROLOUS S-NITROSOGLUTATHION REDUCTASE
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
PL2512502T3 (pl) Sposoby i kompozycje do likwidacji guzów
EP2480086A4 (en) NOVEL DIHYDROPYRIMIDINE-2 (1H) -ONES COMPOUNDS AS INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE
EP2240173A4 (en) PHARMACEUTICAL COMPOSITION OF DULOXETINE WITH DELAYED RELEASE
ZA201208363B (en) Novel intermediates for the preparation of hmg-coa reductase inhibitors
HRP20140842T1 (hr) Sastav za spreäśavanje upale, koji sadrži hijaluronsku kiselinu i inhibitor reduktaze hmg-coa
EP2512247A4 (en) NOVEL THIOPHEN INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE
SI3309253T1 (sl) Geni za biosintezo tetraciklinskih spojin in uporabe le-teh
ZA201006157B (en) Modified release formulations of hmg coa reductase inhibitors
GB2462029B (en) Tracking of an Article
IL213439A0 (en) Methods for enhancing stability of polyorthoesters and their formulations
PL2277511T3 (pl) Kompozycje farmaceutyczne lewetiracetamu o przedłużonym uwalnianiu
EP1940391A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE WITH AN HMG COA REDUCTASE INHIBITOR
HK1174784A (en) Sepiapterin reductase inhibitors for the treatment of pain
HK1158063A (en) Compositions and methods of use for soluble thrombomodulin variants